Resources
18 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/17/2024
This article discusses strategies to recruit primary care providers who will implement a medication for opioid use disorder integrated care model. The Pennsylvania Project, Project RAMP, was guided by a framework highlighting design, recruitment, pre-implementation, and implementation processes. The study covers the implementation sites that were recruited, the planning and implementation activities, and evaluation of the processes.
Posted 4/12/2024
Researchers used data from electronic license renewals in 2021 to examine what factors affect the likelihood of providing medication-assisted treatment (MAT) for opioid use disorder. Physicians and nurse practitioners who were younger, practiced in a public or community health center, and offered a sliding fee scale in their practice had a greater likelihood of providing MAT.
Posted 4/5/2024
The Addiction Technology Transfer Center Network Coordinating Office (ATTC NCO) convened the Contingency Management Task Force (CM Task Force) in April 2023 at the request of the Substance Abuse and Mental Health Services Administration (SAMHSA). The SAMHSA Guidance for Implementation of Contingency Management Training and Technical Assistance was developed by the CM Task Force.
Posted 2/23/2024 (updated 3/28/2024)
Esteemed maternal health professionals in partnership with the de Beaumont Foundation and the MHLIC released The Practical Playbook III: Working Together to Improve Maternal Health. This comprehensive and groundbreaking work serves as a crucial resource for professionals across diverse fields, providing practical and actionable guidance.
Posted 2/9/2024 (updated 3/28/2024)
The U.S. Department of Health and Human Services, through its Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), finalized modifications to the Confidentiality of Substance Use Disorder (SUD) Patient Records regulations at 42 CFR part 2 (“Part 2”), which protect the privacy of patients’ SUD treatment records.
Posted 1/31/2023 (updated 3/27/2024)
These guides from the Substance Abuse and Mental Health Services Administration (SAMHSA) highlights strategies for behavioral health and housing providers to conduct outreach and engage with individuals experiencing homelessness, initiate use of behavioral health treatment as they wait to receive stable housing and retain them in their recovery efforts once housed.
Posted 9/28/2022 (updated 3/27/2024)
Last week, the U.S. Department of Health & Human Services (HHS) introduced the Roadmap for Behavioral Health Integration, to advance the White House Strategy to Address our National Mental Health Crisis announced earlier this year.
Posted 1/25/2022 (updated 3/26/2024)
RCORP-TA is pleased to provide technical assistance resources related to grantee business operations that we have prepared for grantees. RCORP-TA is providing these resources to assist grantees on aspects of their business operations that are continuously impacted and routinely challenged by factors associated with living and working in rural communities. Please see the below linked guidance documents and descriptions as they may be of interest to you.
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 5/12/2021 (updated 4/10/2024)
Drug overdose is a continuing epidemic that claimed the lives of over 67,000 Americans in 2018. Opioids, either alone or in combination with other substances, were responsible for approximately 70% of these deaths. Many of these lost lives and other opioid-related harms are preventable through the timely administration of the opioid reversal drug naloxone and, where appropriate, other follow-up care.